The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 ...
ERAS-0015 is an oral pan-RAS molecular glue currently being evaluated in the AURORAS-1 Phase 1 trial for patients with RAS-mutant solid tumors. The company describes it as a potentially best-in-class ...
Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (ERAS), a clinical-stage precision oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback